7 October 2026

Breach of Listing Rule 7.1

Vitasora Health Limited (ASX: VHL; OTCQB: VHLUF) ("Vitasora" or "the Company") wishes to advise that ASX has brought to the Company's attention a breach of Listing Rule 7.1 which occurred on 18 June 2026 in respect of 28,665,085.75 securities (Relevant Securities). The Relevant Securities were issued to sophisticated, professional and other exempt investors, none of whom are related parties of the Company, and formed part of the issue of 400,000,000 shares as detailed in an Appendix 2A lodged with ASX on 18 June 2026.

The breach does not affect the validity of the share issues. The ASX has confirmed that the issue of the Relevant Securities cannot be ratified by security holders under Listing Rule 7.4, given ratification under Listing Rule 7.4 is only available where the securities are issued or agreed to be issued without breaching Listing Rule 7.1.

For personal use only

Further details of the circumstances of the breach are as follows:

1. On 1 September 2025 VHL obtained shareholder approval at the extraordinary general meeting (EGM) for the issue of of 225,000,000 shares under Tranche 2 of a placement under Listing Rule 7.1 (Resolution 2). Listing Rule 7.3.4 requires that the proposed issue be completed no later than 3 months after the date of the EGM (1 December 2025).
2. The Company issued 81,499,999 shares on 2 March 2026, outside the 3-month period required by Listing Rule 7.3.4 which meant that the approval had lapsed and the securities could no longer be counted in variable A of the formula in Listing Rule 7.1 and instead were counted in variable C of the formula.
3. The Company issued a total of 400,000,000 shares on 18 June 2026, with 220,000,000 shares issued under Listing Rule 7.1 and 180,000,000 shares issued under Listing Rule 7.1A. Whilst the Company had available placement capacity under Listing Rule 7.1 of 191,334,914.25, it had inadequate capacity to issue all 220,000,000 shares under variable C in Listing Rule 7.1 given it incorrectly relied on the shareholder approval for the issue of 81,499,999 shares as disclosed in the Appendix 2A lodged on the ASX market announcements platform on 3 March 2026.
4. As outlined above, the breach on 18 June 2026 was brought to the Company's attention by ASX. The Company notes that subsequent to 18 June 2026 and prior to being notified of the breach, it issued 800,000 shares on 2 July 2026 and 8,250,000 shares on 3 September 2026 under Listing Rule 7.1. As a result, a total of 9,050,000 is added to the Relevant Securities, bringing the total number of shares issued in breach of Listing Rule 7.1, to 37,715,085.75.
5. The excess amount of 37,715,085.75 shares were issued without capacity under Listing Rule 7.1 and cannot be ratified by shareholders at a general meeting. 37,715,085.75 will be counted in variable C until 18 June 2027, 9,050,000 will be counted in variable C until 2 July 2027, and 8,250,000 will be counted in variable C until 3 September 2027.

The non-compliance arose from an interpretive error in applying the relevant Listing Rules, including a change in Company Secretary during this period, to the issue of the Relevant Securities. The Company confirms it has established governance and compliance processes to ensure compliance with the Listing Rules, including professional company secretarial support, and seeks advice from external advisors as appropriate. In the circumstances, the Company has reviewed its corporate governance policies and procedures and considers them adequate to ensure ongoing compliance with Listing Rule 7.1.

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Vitasora Health Limited
P: +61 408 462 873
E: marjan@vitasorahealth.com

Mr Nicholas Smedley
Non-Executive Chairman
Vitasora Health Limited
P: +61 447 074 160
E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit https://respiri.co/us/ or for wheezo®

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For personal use only